Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases
J Clin Oncol
.
2018 Apr 1;36(10):1051.
doi: 10.1200/JCO.2017.77.0115.
Epub 2018 Feb 1.
Authors
Lisa Kennedy
1
,
Sumita Bhatta
1
,
Guy Hechmati
1
,
Jacqueline Buchanan
1
Affiliation
1
Lisa Kennedy, Epiphany, Los Angeles, CA; and Sumita Bhatta, Guy Hechmati, and Jacqueline Buchanan, Amgen, Thousand Oaks, CA.
PMID:
29389236
DOI:
10.1200/JCO.2017.77.0115
No abstract available
Publication types
Letter
Comment
MeSH terms
Bone Density Conservation Agents*
Breast Neoplasms*
Cost-Benefit Analysis
Denosumab
Diphosphonates
Female
Humans
Zoledronic Acid
Substances
Bone Density Conservation Agents
Diphosphonates
Denosumab
Zoledronic Acid